(Hypertension. 2002;39:142.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
From the Department of Clinical Pathology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Correspondence to Kazuhiro Takekoshi, MD, Department of Clinical Pathology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Japan. E-mail K-takemd @md.tsukuba.ac.jp
We previously showed that CGP 42112 (an angiotensin type 2 [AT2] agonist) markedly reduces catecholamine biosynthesis by decreasing cGMP production mediated by AT2, a subtype of Ang II receptor that is dominantly expressed in cultured porcine chromaffin cells. To elucidate the relationship of the 2 types of Ang II receptors, angiotensin type 1 (AT1) and AT2, in the synthesis of catecholamine in adrenal medullary cells, we have examined the effect of Ang II plus CV-11974 (an AT1 antagonist that selectively simulates AT2 stimulation) and the effect of Ang II plus PD 123319 (an AT2 antagonist that selectively simulates AT1 stimulation) on catecholamine synthesis. We found that Ang II reduced cGMP production via AT2, in a similar manner to that found with CGP 42112. Stimulation of AT1 significantly upregulated protein kinase C activity. Tyrosine hydroxylase (TH) is a rate-limiting enzyme involved in the biosynthesis of catecholamine, and this catecholamine synthesis depends both on TH enzyme activity and on the levels of TH protein after TH gene transcription. We found that AT2 stimulation significantly inhibited TH enzyme activity, whereas AT1 stimulation significantly upregulated TH enzyme activity. The stimulatory effect of AT1 was completely inhibited by Ro-32-0432 (a protein kinase C inhibitor) and PD 98059 (a MAP kinase kinase-1 [MEK-1] inhibitor). Pretreatment of cells with either 8-Br-cGMP (a membrane-permeable cGMP analog) or Zaprinast (a phosphodiesterase inhibitor) abolished the inhibitory effect of AT2 on TH enzyme activity, indicating that the stimulatory effect of AT2 may be mediated through a reduction in cGMP concentration. Similar to the effect on TH enzyme activity, AT2 stimulation significantly reduced TH mRNA and protein levels and net catecholamine content below basal levels, whereas AT1 stimulation increased them. We confirmed these findings by gel mobility shift assay. Our results show that stimulation of AT2 reduces catecholamine biosynthesis via a decrease in cGMP levels. In contrast, stimulation of AT1 stimulates catecholamine biosynthesis through activation of PKC. Thus, we conclude that AT1 and AT2 have counter-regulatory roles in the synthesis of catecholamine in adrenal medullary chromaffin cells.
Key Words: receptors, angiotensin II tyrosine hydroxylase cyclic GMP angiotensin antagonist catecholamines
This article has been cited by other articles:
![]() |
E. Mendez-Bolaina, J. Sanchez-Gonzalez, I. Ramirez-Sanchez, E. Ocharan-Hernandez, M. Nunez-Sanchez, E. Meaney-Mendiolea, A. Meaney, J. Asbun-Bojalil, A. Miliar-Garcia, I. Olivares-Corichi, et al. Effect of caveolin-1 scaffolding peptide and 17 -estradiol on intracellular Ca2+ kinetics evoked by angiotensin II in human vascular smooth muscle cells Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1953 - C1961. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Gironacci, M. S. Valera, I. Yujnovsky, and C. Pena Angiotensin-(1-7) Inhibitory Mechanism of Norepinephrine Release in Hypertensive Rats Hypertension, November 1, 2004; 44(5): 783 - 787. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. K. Owonikoko, M. E. Fabucci, P. R. Brown, N. Nisar, J. Hilton, W. B. Mathews, H. T. Ravert, P. Rauseo, K. Sandberg, R. F. Dannals, et al. In Vivo Investigation of Estrogen Regulation of Adrenal and Renal Angiotensin (AT1) Receptor Expression by PET J. Nucl. Med., January 1, 2004; 45(1): 94 - 100. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jezova, I. Armando, C. Bregonzio, Z.-X. Yu, S. Qian, V. J. Ferrans, H. Imboden, and J. M. Saavedra Angiotensin II AT1 and AT2 Receptors Contribute to Maintain Basal Adrenomedullary Norepinephrine Synthesis and Tyrosine Hydroxylase Transcription Endocrinology, May 1, 2003; 144(5): 2092 - 2101. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |